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Abstract
Background: Photodynamic therapy (PDT) has proven to be a promising alternative to current cancer treatments,
especially if combined with conventional approaches. The technique is based on the administration of a non-toxic
photosensitizing agent to the patient with subsequent localized exposure to a light source of a specific
wavelength, resulting in a cytotoxic response to oxidative damage. The present study intended to evaluate in vitro
the type of induced death and the genotoxic and mutagenic effects of PDT alone and associated with cisplatin.
Methods: We used the cell lines SiHa (ATCC® HTB35™), C-33 A (ATCC® HTB31™) and HaCaT cells, all available at Dr.
Christiane Soares’ Lab. Photosensitizers were Photogem (PGPDT) and methylene blue (MBPDT), alone or combined
with cisplatin. Cell death was accessed through Hoechst and Propidium iodide staining and caspase-3 activity.
Genotoxicity and mutagenicity were accessed via flow cytometry with anti-gama-H2AX and micronuclei assay,
respectively. Data were analyzed by one-way ANOVA with Tukey’s posthoc test.
Results: Both MBPDT and PGPDT induced caspase-independent death, but MBPDT induced the morphology of
typical necrosis, while PGPDT induced morphological alterations most similar to apoptosis. Cisplatin predominantly
induced apoptosis, and the combined therapy induced variable rates of apoptosis- or necrosis-like phenotypes
according to the cell line, but the percentage of dead cells was always higher than with monotherapies. MBPDT,
either as monotherapy or in combination with cisplatin, was the unique therapy to induce significant damage
to DNA (double strand breaks) in the three cell lines evaluated. However, there was no mutagenic potential
observed for the damage induced by MBPDT, since the few cells that survived the treatment have lost their
clonogenic capacity.
Conclusions: Our results elicit the potential of combined therapy in diminishing the toxicity of antineoplastic
drugs. Ultimately, photodynamic therapy mediated by either methylene blue or Photogem as monotherapy or in
combination with cisplatin has low mutagenic potential, which supports its safe use in clinical practice for the
treatment of cervical cancer.
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Background
Photodynamic Therapy (PDT) is a treatment modality
considered an alternative to current treatments for
cancer and infections. Briefly, it is based on the adminis-
tration of a non-toxic dye (photosensitizing agent) to the
patient with subsequent local exposure to a light source
of specific wavelength [1], leading to the death of target
cell via oxidative damage. PDT presents several advan-
tages for the treatment of both tumors and infections,
among which are noteworthy the minimum systemic
adverse effects due to its double selectivity, resulting in
localized treatment [2, 3].
Photodynamic therapy has been identified as a promis-
ing adjuvant therapy of conventional approaches due to
its multiple mechanisms of action that individual drugs
usually do not present. Therefore, the combination of
therapies with different mechanisms of action may offer
an advantage over monotherapies, since most diseases
involve multiple and distinct pathologic processes [4].
Combining different approaches can result in benefits
such as reaching several cellular targets, providing greater
efficiency in destroying target cells and reducing
doses of individual therapy components, with an over-
all improvement on therapeutic response and reduc-
tion of toxic effects [5].
With either a monotherapy or a combined modality,
cancer treatment success is determined by the inter-
action of host immune cells and dying cancer cells,
which can be achieved by merging the cytotoxic effect
with immune stimulation capable of eliminating residual
cells or possible micrometastasis [6, 7]. In fact, tumors
responsive to PDT treatment are those presenting a
great infiltrate of immune cells after the treatment [8].
Therefore, the ability of a cancer treatment to elicit host
immune system stimulation via immunogenic cell death
presents fundamental clinical relevance, since the an-
ticancer immune response reinforces the therapeutic
effect [7].
Besides inducing an immunogenic cell death, cancer
therapies must not elicit additional mutations on surviv-
ing cells, since new mutations can result in cancer resist-
ance to chemotherapy and, consequently, contribute to
disease progression. Additionally, precaution is necessary
regarding genotoxic damage, which could lead to the
emergence of a secondary tumor, as an adverse effect of
the anticancer agent on normal cells [9, 10].
PDT has the potential to attend all the requisites de-
scribed above, either alone or combined with different
approaches, as evidenced by a previous study of our
group [5]. Then, we demonstrated that combining PDT
with cisplatin significantly improved cell death, but in-
formation regarding the type of cell death induced by
the combination treatment was lacking. Therefore, the
aim of this study was to investigate the type of cell death
induced by PDT and PDT combined with cisplatin, as
well as their potential to induce mutations in surviving
cells, using cervical cancer cell lines as a model.
Methods
Cell cultures
The cell lines used in this study were provided by Dr.
Christiane Pienna Soares and were: SiHa (cervical car-
cinoma infected with HPV16; ATCC® HTB35™), C-33 A
(cervical carcinoma not infected with HPV; ATCC®
HTB31™), and HaCaT (spontaneously immortalized hu-
man keratinocytes; Addexbio Catalog #:T0020001). Cell
lines were routinely checked for mycoplasma contamin-
ation. All cell lines were grown in a 1:1 mixture of
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma Co.,
St. Louis, USA) and Ham’s Nutrient Mixture F10 (Sigma
Co., St. Louis, USA) supplemented with 10% fetal bovine
serum (FBS; Cultlab, Campinas, Brazil), 1X antibiotic/anti-
mycotic solution (100 U/mL penicillin, 100 μg/mL
streptomycin, 0.25 μg/mL amphotericin B; Sigma Co., St.
Louis, USA) and 0.1 mg/mL kanamycin (Sigma Co., St.
Louis, USA), which is referred to as “complete medium”
hereafter. Cells were kept in 5% CO2 atm, 95% relative hu-
midity and a constant temperature of 37 °C.
Photosensitizers and drugs
All drugs and photosensitizers were prepared and stored
protected from light.
Photogem (PG; Photogem LLC. Co., Moscow, Russia)
and Methylene blue (MB; Sigma Co., St. Louis, USA) were
dissolved in PBS and stored at −20 °C. Cisplatin (CisPT)
was obtained as a 0.5 mg/mL solution (Tecnoplatin,
Zodiac Produtos Farmaceuticos S/A, Brazil), stored at
room temperature. Curcumin (CUR; Sigma Co., St. Louis,
USA) was solubilized in dimethyl sulfoxide (DMSO) and
stored at −20 °C. All drugs above were diluted to working
concentrations prior to use. Doxorubicin (DOX) was
obtained as doxorubicin hydrochloride powder (Cloridrato
de doxorrubicina, Eurofarma, Brazil) and solutions were
prepared in sterile distilled water immediately prior to use.
Light source
Both light sources (630 and 660 nm) consisted of a com-
pact LED array-based illumination system with a homoge-
neous illumination area and a cooling device, composed
of 48 LEDs with variable intensities (IrradLED® – biopdi,
Sao Carlos, SP, Brazil). The distance between the LED
and the plate allowed an even distribution of light on
each well. The power density of the incident radiation
was measured using a power meter (Coherent®, Santa
Clara, CA, USA).
Photodynamic therapy and cisplatin treatment
Treatment groups are summarized in Table 1.
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In the cisplatin-only group, cells were treated with
41.6 μM of cisplatin for 6 h. For the PG-photodynamic
therapy (PGPDT) group, the cells were exposed to
630 nm at 2.76 J/cm2 after 2 h of incubation with
0.5 μM of PG. In the MB-photodynamic therapy
(MBPDT) group, the cells were exposed to 660 nm at
5.11 J/cm2 after 20 min of incubation with 19.5 μM of
MB. In the combination group, 1.3 μM of cisPT was ad-
ministered for 6 h immediately after MBPDT or 6 h be-
fore PGPDT. All treatment conditions were determined
based on previous studies of our group [5].
Death profile assays
Fluorescence microscopy with Hoechst 33342 and
propidium iodide
This assay was performed in a semi-automatic way at
the IN Cell Analyzer 2000 (GE Healthcare Life Sciences,
Pittsburgh, PA, EUA). For the assay, cells were cultivated
in 96 wells plates in a cell density of 5,000 cells per well
(5.0 × 104 cell/mL) and, after 24 h of incubation at 37 °C
and 5% CO2, treated according to the section Photo-
dynamic Therapy and cisplatin treatment. After incuba-
tion time was complete, the plate was centrifuged at
2,500 rpm for 5 min at 4 °C. Media containing treatment
was removed carefully and 100 μL of ice-cold PBS 1X
were added to each well. The plate was centrifuged once
more and PBS was removed. In a dark room, 100 μL of
fluorochromes mix (HO 1 mg/mL – 15%; PI 1 mg/mL
25%, FDA 1 mg/mL 35%) prepared in ice-cold PBS was
added to each well and plate was incubated at room
temperature in the dark for 10 min. IN Cell Analyzer
2000 was set to capture 12 fields per well in each of the
four wavelengths (bright field, green, blue and red filters)
using a 20X objective. Images obtained were merged
using IN Cell Analyzer 1000 Workstation 3.7 software
(GE HealthCare, Pittsburgh, PA, EUA) and cells were
counted manually. Five hundred cells were counted in
each well and cell death was analyzed through the deter-
mination of live, apoptotic or necrotic cells based on cell
morphology and fluorescence. The assay was performed
in triplicates and was repeated three times.
Caspase-3 activity
Cells at a density of 2 × 105 cell/mL were plated in 96
wells plates with a black bottom and incubated for 24 h
at 37 °C and 5% CO2. Cells were treated according to
the section Photodynamic Therapy and cisplatin treat-
ment and placed over ice immediately after treatment
period was over. Media containing treatment solutions
were removed and each well received 100 μL of lysis
buffer (50 mM Tris pH 7.4; 150 mM NaCl; 0.5% Triton
X-100; EDTA 2 mM; DTT 5 mM). The plate was incu-
bated on ice for 20 min and then 100 μL of substrate
(20 μM Acetyl-Asp-Met-Gln-Asp-amino-4-methylcou-
marin [Ac-DMQD-AMC]) prepared in lysis buffer were
added to each well, in the dark. After substrate addition,
the plate was read in a fluorometer (FLx800™ Fluorescence
Reader, BioTek - Winooski, VT, USA; excitation 360/
40 nm and emission 460/40 nm) by top reading after 30 s
of gentle agitation. Reading was performed at 37 °C. Re-
sults were expressed as released 7-amino-4-methylcou-
marin (AMC) concentration, based on the standard curve,
which was prepared with decreasing concentrations of
AMC beginning with 4 μM and ending in 0.0156 μM
(2-fold dilutions). The assay was performed in tripli-
cates and was repeated three times.
Genotoxicity assays
Flow cytometry using anti-γH2AX antibody
Cells at a density of 2 × 105 cells/well were plated in 24
wells plates, incubated for 24 h at 37 °C and 5% CO2,
and treated according to section Photodynamic Therapy
and cisplatin treatment. After treatment, cells were col-
lected from the wells via trypsinization and centrifuged
at 2.500 rpm for 10 min. Cells pellets were suspended in
1 mL of 4% paraformaldehyde and incubated for 10 min
at room temperature. Cells were centrifuged again at
2.500 rpm for 10 min and washed once with 1X PBS.
Each cell pellet was then suspended in methanol 70%
(obtained with 30% 1X PBS) and stored at −20 °C until
flow cytometry analysis. In the following step, cells were
centrifuged at 2.200 rpm for 5 min and washed with 1X
PBS. For permeabilization, cells were suspended in
0.025% Triton-X-100 and incubated for 5 min at room
temperature, being once more centrifuged at 2.200 rpm
for 5 min. Cells were incubated with anti-γH2AX anti-
body (2.5:1000) for 1 h at room temperature, without
agitation. Again, cells were centrifuged at 2.200 rpm for
5 min and washed with 1X PBS. Then, cells were incu-
bated with secondary antibody conjugated with Alexa
Fluor® 488 (2.5:1000) for 30 min at room temperature,
without agitation. Cells suspensions were centrifuged at
2.200 rpm for 5 min and washed with 1X PBS, being
Table 1 Treatment groups for photodynamic therapy and
cisplatin monotherapies and combination therapies
GROUPS [PS] [CisPT] LIGHT DOSE
methylene blue (MB) 19.5 μM 0 0
Photogem (PG) 0.5 μM 0 0
MBPDT 19.5 μM 0 5.11 J/cm2
PGPDT 0.5 μM 0 2.76 J/cm2
cisplatin (CisPT) 0 41.6 μM 0
MBPDT + CisPT 19.5 μM 1.3 μM 5.11 J/cm2
CisPT + PGPDT 0.5 μM 1.3 μM 2.76 J/cm2
PS: photosensitizer; MBPDT: methylene blue-mediated photodynamic therapy;
PGPDT: Photogem-mediated photodynamic therapy.
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suspended in 60 μL of 1X PBS and analyzed by flow cy-
tometry in a FACSCanto (BD - Becton, Dickinson, and
Company, New Jersey, USA). The assay was performed
in triplicates and was repeated three times.
Micronuclei assay
Five hundred cells were distributed in each well of a 96
wells plate. After 24 h of incubation at 37 °C and 5%
CO2, cells were treated according to section Photo-
dynamic Therapy and cisplatin treatment; media con-
taining treatment substances were removed and replaced
by complete medium. Cells were left to recover for 24 h.
The next day, each well received 100 μL of complete
medium containing 6 μg/mL cytochalasin B (Sigma Co.,
St. Louis, USA) and the plate was incubated for
additional 24 h. After incubation, cells were fixed with
absolute ethanol for 30 min and stained with 1 mg/mL
fluorescein isothiocyanate (FITC) for 30 min, and
10 μg/mL Hoechst 33342 for 15 min. All procedures were
performed at room temperature in the dark. Reading was
performed in the IN Cell Analyzer 2000, which was set to
capture 12 fields per well in each of the three wavelengths
(bright field, green and blue filters) using a 20X objective.
Images obtained were fused using IN Cell Analyzer 1000
Workstation 3.7 software (GE HealthCare, Pittsburgh, PA,
EUA) and cells were analyzed manually. The assay was
performed in triplicates and was repeated three times.
Clonogenic survival
Cells were plated in duplicates at a density of 150 cells/
well in six wells plates and incubated until attached to the
bottom of the well (3 h at 37 °C and 5% CO2; adhesion
was confirmed by microscopic observation). Once ad-
hered, cells were treated according to section Photo-
dynamic Therapy and cisplatin treatment and, after each
treatment time, the medium was removed and replaced by
complete medium. The plates were incubated at 37 °C
and 5% CO2 for 7 days, without media exchange. After
the 7 days, the medium was removed and cells were
washed with 1X PBS, fixed with a mixture of methanol,
acetic acid and water (1:1:8, respectively) for 30 min
and stained with crystal violet for 15 min. Established
colonies were analyzed using a magnifying lens (16X
magnification). Colonies containing < 50 cells were not
considered and results were expressed in plating effi-
ciency (PE) and survival fraction (SF), according to
Franken et al. [11]. The assay was performed in du-
plicates and was repeated three times.
Statistical analysis
Data were expressed as the mean plus standard deviation
(SD) and were analyzed by one-way ANOVA with Tukey’s
posthoc or Kruskal-Wallis with Dunn’s posthoc test
using GraphPad Prism® Version 5.01 software (GraphPad
Software Inc., La Jolla, CA, USA). Differences were
considered to be significant when p < 0.05. The acceptable
coefficient of variation was less than or equal to 25%.
Results
In previous studies of our group, we observed that both
the photodynamic therapy mediated by methylene blue
(MBPDT) and Photogem (PGPDT) were effective in redu-
cing cell viability with cytotoxicity being dependent on the
light dose, for all three cell lines analyzed (C-33 A, HaCaT
and SiHa). Cisplatin was less effective over the three cell
lines compared to PDT (Fig. 1). However, the combination
cisplatin + PDT had a synergistic effect and caused greater
cell death in all conditions tested (Fig. 1). The sequence of
treatment application (PDT + cisplatin or cisplatin + PDT)
influenced the response and effectiveness depended on
the photosensitizer: for MBPDT we found that PDT prior
to cisplatin was more effective; on the other hand, for
PGPDT the efficiency increased when cisplatin treatment
was performed before PDT [5]. Therefore, the aim of this
study was to investigate the type of cell death induced by
PDT and PDT combined with cisplatin, as well as their
potential to induce mutations in surviving cells, using
cervical cancer cell lines as a model.
Cell death profile characterization
Fluorochrome exclusion assay: Hoechst 33342 and
propidium iodide
As expected, cells treated with doxorubicin and curcu-
min induced, primarily, necrosis and apoptosis, respect-
ively, with the percentage of necrotic or apoptotic cells
varying according to the cell line (Figs. 2 and 3), with C-
33 A being the most sensitive one (Figs. 2 and 3a).
When cells were treated only with LED light sources or
photosensitizers in the dark we did not observe signifi-
cant cell death in comparison with the negative control
cells (Figs. 2 and 3a-c).
MBPDT induced a greater amount of cell death in
SiHa cells, compared to C-33 A and HaCaT, accordingly
to our previous results. However, opposing previous
studies [12–14], MBPDT caused cell death with predom-
inant necrotic morphology, with about 2/3 of dead cells
identified as necrotic and 1/3 presenting morphology of
typical apoptosis (Fig. 2).
The combination therapy of MBPDT and cisplatin
kept the death profile, with a predominance of necrotic
cells for SiHa and HaCaT, but cell death percentage was
even higher than that with both MBPDT and cisplatin as
monotherapies (Figs. 2, 3b-c). C-33 A also presented
higher levels of cell death when submitted to the com-
bined therapy in comparison to monotherapies; however,
there was a predomination of typical apoptosis morph-
ology, a death profile more similar to that of cisplatin
monotherapy (Figs. 2 and 3a).
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When cell lines were treated with PGPDT we also ob-
served cells with both necrotic and apoptotic morpholo-
gies, but with a predominance of the apoptotic type
(Figs. 2 and 3a-c). Contrary to what was observed for
MBPDT + cisplatin, combined therapy of cisplatin and
PGPDT did not induce a greater percentage of cell death
when compared to PGPDT monotherapy, except for C-33
A, which again presented a distinct behavior from the
other two cell lines. When compared to cisplatin as
monotherapy, cisplatin + PGPDT was capable of inducing
increased rates of cell death for all cell lines evaluated.
Caspase-3 activity assay
The Nomenclature Committee on Cell Death (NCCD)
recommends that apoptosis, or other types of cell death,
has to be demonstrated by more than one methodology
as a procedure to eliminate artifacts. Therefore, to com-
plement and confirm the results of cytomorphological
fluorochromes exclusion assay described above, we con-
ducted a caspase-3 activity assay.
With the only exception of positive control (curcu-
min), none of the treatments induced detectable capase-
3 activation. Concerning negative control (NC), MB, PG,
LED630 and LED660 the result confirmed the observed
non-induction of cell death; similarly, doxorubicin did
not induce caspase activation as expected, since it
promotes death by necrosis, which is independent of
caspases. Although cisplatin had promoted apoptosis
as monotherapy, the slight toxic effect observed over
the cell lines used in this study generated a few
Fig. 1 Comparison of cytotoxic effects of Photodynamic Therapy and cisplatin, as monotherapies and combined. a cell lines were treated with
MBPDT (19.5 μM; 5.11 J/cm2), cisplatin (1.3 μM for 6 h) and combined therapy (MBPDT + CisPT, using the same parameters of monotherapies). b
cell lines were treated with PGPDT (0.5 μM; 2.76 J/cm2), cisplatin (1.3 μM for 6 h) and combined therapy (CisPT + PGPDT, using the same
parameters of monotherapies). It is observed a great reduction in cell viability caused by combined therapies, compared to monotherapies.
Asterisks indicate the statistical differenc. Columns represent the average of four independents quadruplicates and bars represent the standard
deviation. ANOVA one-way, with Tukey posthoc. *p < 0,05; **p < 0,01; ***p < 0,001
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apoptotic cells that probably did not produce a de-
tectable signal.
Treatments with photodynamic therapy, either as
monotherapy or combined with cisplatin, did not activate
caspase-3. Such result indicates the cell death caused by
PDT in the conditions employed in this study is caspase-
independent, which agrees with previous studies that
associated caspase-independent cell death (CICD) with in-
creased amounts of reactive oxygen species [15–17],
which are responsible for PDT’s mechanism of action.
Genotoxicity
Flow cytometry with anti-γH2AX
Table 2 shows the results of γH2AX labeling obtained
for C-33 A, HaCaT e SiHa cells. Average fluorescence
intensity is directly proportional to the frequency of
DNA’s double strand breaks induced by the treatments
[18–20]. Cells treated with light, the photosensitizers
or cisplatin only did not suffer significant DNA dam-
age, with the concentrations employed, comparing to
non-treated cells.
Fig. 2 Fluorescence images obtained from IN Cell Analyzer, using Hoechst 33342, propidium iodide and fluorescein diacetate. Cell lines C-33 A,
HaCaT and SiHa were submmited to Hoechst 33342, propidium iodide and fluorescein diacetate staining after treatments (CUR [25 μM for 6 h];
DOX [50 μg/mL for 6 h]; CisPT [41.6 μM for 6 h]; MBPDT [19.5 μM MB + 5.11 J/cm2 LED 660 nm]; MBPDT + CisPT [19.5 μM MB + 5.11 J/cm2 LED
660 nm+ 1.3 μM CisPT for 6 h]; PGPDT [0.5 μM PG+ 2.76 J/cm2 LED 630 nm]; CisPT + PGPDT [1.3 μM CisPT for 6 h + 0.5 μM PG+ 2.76 J/cm2 LED
630 nm]). White arrows indicate representative apoptotic cells and yellow arrows indicate representative necrotic cells. 20X objective. NT: non-treated;
CUR: curcumin; DOX: doxorubicin; CisPT: cisplatin; MBPDT: photodynamic therapy mediated by methylene blue; PGPDT: photodynamic therapy mediated
by Photogem
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On the other hand, it is possible to observe that
MBPDT induced pronounced DNA double strand
breaks in all cell lines, in an opposite way of PGPDT,
which did not cause DNA damage. Similarly, the
combined therapy MBPDT + cisplatin induced a higher
number of breaks than the combined therapy PGPDT +
cisplatin, which resulted in a damage index comparable
to that of PGPDT.
To verify the mutagenic potential of the therapies evalu-
ated here, treatments that caused DNA damage were ana-
lyzed regarding their ability to induce mutations, which
was done using the micronuclei assay, described below.
Fig. 3 Cell death profile induced by each treatment, according to
cell line. Cell lines C-33 A (panel a), HaCaT (panel b) and SiHa (panel c)
were submmited to Hoechst 33342, propidium iodide and fluorescein
diacetate staining after treatments (CUR [25 μM for 6 h]; DOX [50 μg/
mL for 6 h]; CisPT [41.6 μM for 6 h]; MB [19.5 μM for 20 min]; LED
660 nm [5.11 J/cm2]; PG [0.5 μM for 2 h]; LED 630 nm [2.76 J/cm2];
MBPDT [19.5 μM MB+ 5.11 J/cm2 LED 660 nm]; MBPDT + CisPT
[19.5 μM MB+ 5.11 J/cm2 LED 660 nm+ 1.3 μM CisPT for 6 h]; PGPDT
[0.5 μM PG + 2.76 J/cm2 LED 630 nm]; CisPT + PGPDT [1.3 μM CisPT for
6 h + 0.5 μM PG+ 2.76 J/cm2 LED 630 nm]). Columns represent the
average of three independent assays and bars represent standard
deviation. Asterisks indicate the statistical difference, relative to
negative control. Kruskal-Wallis, with Dunn’s post-hoc. *p < 0,05;
**p < 0,01; ***p < 0,001. NT: non-treated; CUR: curcumin; DOX:
doxorubicin; CisPT: cisplatin; MB: methylene blue; MBPDT: photodynamic
therapy mediated by MB; PG: Photogem; PGPDT: photodynamic therapy
mediated by PG
Table 2 Detection of H2AX phosphorylation via flow cytometry
Average fluorescence intensity
Treatments C-33 A SiHa HaCaT
No treatment 1256 1405 1545
Secondary antibody 1197 1465 1391
CisPT 1503 1575 1526
LED660 1318 1533 1591
MB 1211 1401 2069
MBPDT 2471** 2531** 2842*
MBPDT + CisPT 3362** 3115** 10547***
LED630 1376 1489 1669
PG 1452 1414 1677
PGPDT 1386 1428 1695
CisPT + PGPDT 1444 1534 10547
Cell lines C-33 A, HaCaT and SiHa were submmited to flow cytometry using
anti-γH2AX monoclonal antibody after treatments (CisPT [41.6 μM for 6 h]; MB
[19.5 μM for 20 min]; LED 660 nm [5.11 J/cm2]; PG [0.5 μM for 2 h]; LED 630 nm
[2.76 J/cm2]; MBPDT [19.5 μM MB+ 5.11 J/cm2 LED 660 nm]; MBPDT + CisPT
[19.5 μM MB+ 5.11 J/cm2 LED 660 nm+ 1.3 μM CisPT for 6 h]; PGPDT [0.5 μM
PG+ 2.76 J/cm2 LED 630 nm]; CisPT + PGPDT [1.3 μM CisPT for 6 h + 0.5 μM PG+
2.76 J/cm2 LED 630 nm]). Asterisks indicate the statistical difference relative to
non-treated samples. Kruskal-Wallis, with Dunn’s post-hoc (ns: non significative;
*p < 0,05; **p < 0,01; ***p < 0,001). CisPT: cisplatin; MB: methylene blue; MBPDT:
photodynamic therapy mediated by MB; PG: Photogem; PGPDT: photodynamic
therapy mediated by PG
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Micronuclei assay
For this assay, we considered only the treatments that
induced DNA double strand breaks detected in the flow
cytometry with anti-γH2AX, i.e., MBPDT and MBPDT
combined with cisplatin. However, we could not perform
micronuclei counting after those treatments given that
this damage is detected only when cells execute mitosis.
Thus, it is mandatory that treated cells have kept their
cellular division capacity after treatment. Nevertheless,
as can be seen in Fig. 4, we could not find a single
binucleated cell after MBPDT or MBPDT + cisplatin
treatments, unlike the negative control cells.
In order to confirm that such outcome was indeed a
result of the loss of cell division capacity, we performed
a clonogenic survival assay. It was confirmed that cells
have lost their normal cell division capability since the
few surviving cells failed to divide even after 7 days of
incubation (Fig. 5).
Discussion
In a previous study of our group [5], we employed the
MTT assay to assess cell viability of C-33 A, HaCaT, and
SiHa after treating those cell lines with PDT mediated
either by methylene blue or Photogem, alone or com-
bined with cisplatin. The cell viability of the combined
therapy groups was significantly lower compared to
monotherapies. The sequence of treatments (PDT + cis-
platin or cisplatin + PDT) was important and had different
results when varying the PS, but combination therapy re-
sulted in an enhanced anticancer effect regardless of the
treatment protocol, enabling the use of cisplatin at a con-
centration 12.5-fold lower compared with cisplatin-only
treatment. In the following step, we sought to investigate
how the cells were dying and whether or not the therapies
could induce mutations.
Regarding the type of induced cell death, MBPDT in-
duced the typical morphology of necrosis (Figs. 2 and 3).
Contrary of what is described in previous studies [12–14],
MBPDT caused cell death with predominantly necrotic
morphology, with about 2/3 of dead cells identified as nec-
rotic and 1/3 presenting morphology typically apoptotic
(Fig. 2c). Such difference can be due to the incubation
time with the photosensitizer prior to LED irradiation.
Differently of our work, most of the previous cell culture
studies employed protocols with dark incubation of 1 h
[13, 21]. The incubation for 20 min employed in this work
may have been insufficient for MB to reach the cellular
targets needed to trigger cell death by apoptosis. There-
fore, if MB was restricted to the cytoplasmic membrane
proximities at the moment of irradiation, it is possible that
reactive oxygen species (ROS) and singlet oxygen formed
might have induced peroxidation of membrane lipids [22],
which could have led to loss of membrane integrity and
favored cell death by necrosis [23].
Cisplatin predominantly induced apoptosis, and com-
bined therapy induced different rates of apoptosis- or
necrosis-like depending on the cell line, but always with
a higher percentage of dead cells than monotherapies
(Figs. 2 and 3). Those results highlight the synergistic ef-
fect between PDT and cisplatin and corroborate the data
obtained in the cytotoxicity assays (Fig. 1). Moreover,
the different cell death profiles observed among the
three cell lines after treatment with combined therapies
indicate that the cytotoxic effects elicited by each indi-
vidual therapy are dependent on the cell type.
Morphology alterations induced by PGPDT were most
similar to apoptosis (Figs. 2 and 3). Several studies have
shown that Photogem can induce both types of cell
death [24, 25]. Therefore, our results were as expected
and were in concordance with the literature. In this
study, in general, cell death rates obtained for PGPDT,
both as monotherapy and combined with cisplatin, were
unexpectedly low, taking into account the results ob-
tained in the cytotoxicity assay (Fig. 1). It is possible that
PGPDT induces cellular damages that culminate in cell
death in later times, which could have generated the low
estimative of the post-treatment death rate in this assay
due to the incubation times employed.
Members of the cysteine protease family, caspases
have a central role in the coordination of stereotyped
events occurring during apoptosis [26]. Caspases are ac-
tivated in response to various cell death stimuli and lead
to disassembly of the cell by proteolysis of hundreds
cellular targets [27, 28]. According to the phase of the
Fig. 4 Micronuclei assay. Representative images of micronuclei assay.
Yellow arrows indicate a few binucleated cells. Images captured
using IN Cell Analyzer 2000, 20X objective. NT: non-treated; MBPDT:
photodynamic therapy mediated by methylene blue (19.5 μM MB+
5.11 J/cm2 LED 660 nm) MBPDT + CisPT: MBPDT followed by cisplatin
treatment for 6 h (1.3 μM CisPT)
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apoptotic process in which they operate, caspases are
subdivided into initiator (caspases −8, −9 and −10),
which connects the intrinsic or extrinsic cell death stim-
uli to the following caspases in the pathway, so-called ef-
fectors (caspase - 3, −6 and −7), which activate other
cellular factors [26]. Caspase-3, for example, promotes
cleavage of PARP1 (poly (ADP-ribose) polymerase 1)
and internucleosomal DNA fragmentation, one of the
hallmarks of apoptosis [29]. Thus, detection of caspase-3
activity is a hallmark of classical apoptosis occurrence by
the caspase-dependent pathway.
In this study, both MBPDT and PGPDT did not activate
capase-3 in any of the cell lines, indicating that those treat-
ments induced caspase-independent cell death (CICD).
CICD is defined by some authors as the cell death that
occur when stimuli that would usually cause apoptosis
fails to activate the caspase [29]. Although typical events
of caspase action are not present, like phosphatidylserine
externalization and nuclear fragmentation, other charac-
teristics of CICD resembles those of apoptosis, such as
permeabilization of the mitochondrial outer membrane,
loss of proliferation capacity and nuclear condensation
[29, 30]. However, cells undergoing CICD may present a
wide variety of characteristics, depending mainly on the
initial stimuli and cell type [29]. On Fig. 2 we can see
treatment protocols involving MBPDT resulting in cell
death with morphology similar to necrosis, while the
protocols involving PGPDT produced cell morphologies
more similar to those of apoptotic cells, which demon-
strates that initial stimuli seem to be more important
than cell type to determinate the characteristics of the
death process that the cells will undergo.
Fig. 5 Clonogenic survival. a Survival fraction of cell lines treated or not with MBPDT or MBPDT + CisPT. Columns represent the average number
of colonies in each condition (a colony was considered so when presenting more than 50 cells), after three independent assays. Bars indicate the
standard deviation. Asterisks indicate the statistical difference, relative to negative control. Kruskal-Wallis, with Dunn’s posthoc (*p < 0,05; **p < 0,01;
***p < 0,001). b Representative images of colonies formed in each treatment condition. Cristal violet staining; 10X objective (Olympus CKX31
microscope). NT: non-treated; MBPDT: photodynamic therapy mediated by methylene blue (19.5 μM MB+ 5.11 J/cm2 LED 660 nm) MBPDT +
CisPT: MBPDT followed by cisplatin treatment for 6 h (1.3 μM CisPT)
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Specialized literature brings a huge discussion con-
cerning the type of cell death induced by photodynamic
therapy and the subsequent antitumor immune response
triggered. It is commonly accepted that cell death via ne-
crosis prompts acute inflammatory response and, there-
fore, has an immunogenic role. Likewise, it is known
that apoptotic cells are cleared from the tissue in a silent
way, without leading to an inflammatory environment or
an immunological response [31, 32]. However, the idea
of immunogenic apoptosis was raised by several authors
and has gained strength in recent years [1, 33, 34].
The concept of caspase-independent cell death is re-
cent and, therefore, there are little enlightening studies
on the subject. It is not known how the tissue responds
to those cells, how they are removed from the tissue and
what is the role of CICD in the development of antitu-
mor immunity [15, 29]. However, since it presents char-
acteristics both of apoptosis and necrosis, it is possible
that CICD plays an important role in the development
of antitumor immunity. In fact, it was observed that
some cell lines that die in a caspase-independent man-
ner are highly immunogenic [35].
Besides conflicting ideas, there is a consensus over the
fact that the generation of an intense acute inflammatory
response after photodynamic therapy exerts a positive
role in immune system activation and, by doing so, trig-
gers the establishment of a lasting antitumor immunity,
with potential to control possible recurrences of the pri-
mary malignant tumor and micrometastasis [1, 7].
Therefore, treatment protocols that favor tumor cell
death by both apoptosis and necrosis, as the protocols
shown in this work, have a great potential to induce an-
titumor immunological response: necrotic cells would
provoke the necessary inflammatory response to attract
defense cells, and apoptotic cells being phagocytized by
professional antigen presenting cells would trigger the
development of specific antitumor immunological re-
sponse. Nevertheless, more studies are required to deter-
mine if the type of cell death observed for the PDT
treatments of this work would be the key for the estab-
lishment of a lasting and effective antitumor immunity.
MBPDT, either as monotherapy or in combination with
cisplatin was the unique therapy to induce significant
damage to DNA (double strand breaks) in the three cell
lines (Table 2). Several studies have evaluated the geno-
toxic potential of photodynamic therapy, using a variety of
photosensitizers, light sources and cell lines. Induction of
DNA damage by PDT was identified in all works available
so far, with singlet oxygen being the species directly re-
lated to alterations observed in the DNA. The type and
extension of DNA damage vary accordingly to the PS and
its concentration, light dose and cell line [36–39].
Results obtained in this work corroborate the previous
studies mentioned, particularly concerning MBPDT. The
great extension of DNA damage induced by this therapy
was accompanied by increased cell death, mainly with a
necrotic profile, either as monotherapy or combined
with cisplatin. Preceding studies have shown that exten-
sive DNA damage caused by oxidative stress lead to cell
death by necrosis: after genomic injury PARP-1 is acti-
vated and catalyzes the hydrolysis of NAD+, depleting it
from cellular context and causing an energetic failure.
That process results in caspase-independent cell death
with necrotic features [40–45].
Besides double and single strand breaks, PDT can in-
duce DNA cross-linking, sister chromatid exchange and
base oxidation in the DNA, particularly in guanine
residues; various studies suggest the formation of the 8-
hydroxydeoxyguanosine residue after PDT mediated by
methylene blue [36–38, 46]. Thus, we can speculate that,
although PGPDT did not cause DNA double strand
breaks, other types of DNA damage could be generated
by this treatment. This is an interesting hypothesis to be
tested in further studies.
To determine if the observed genotoxic action could
be mutagenic, we performed the micronuclei (MN) for-
mation assay. MN can originate from acentric chromo-
somal fragments (missing the centromere) or whole
chromosomes incapable of migrating to cell poles during
anaphase of cell division. Therefore, micronuclei repre-
sent a permanent damage that has been transmitted to
the cell’s offspring [47]. There was no mutagenic poten-
tial for the damage induced by MBPDT, given that the
few cells that survived the treatment have lost their clo-
nogenic capacity (Figs. 4 and 5).
Therefore, although MBPDT and MBPDT + cisplatin
treatments induce extensive DNA damage, the few cells
that survive the treatment cannot propagate the ac-
quired mutations because they do not have any prolifer-
ative capacity. By knowing the mechanism of cell death
caused by the combined therapy one would have more
certainty that this new approach will not cause add-
itional mutations to the cancer cells or their surrounding
normal cells, which could complicate the treatment. In
addition, although it requires further studies, combining
PDT with cisplatin may have a positive effect on the de-
velopment of specific antitumor immunity, preventing
the recurrence of the primary tumor.
Since cisplatin have been used to treat patients with
cervical cancer for decades [5], and PDT have been used
to treat early cervical cancer in clinical studies ([48–52];
among others), we believe it is completely possible to re-
produce our results in vivo. By doing so, the cisplatin
dose administered to the patients would be reduced due
to its association with PDT because cells are being
attacked by two different mechanisms, diminishing the
required dose to trigger cell death. This has a very im-
portant impact on reducing adverse effects provoked by
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antineoplastic drugs since less deleterious effects are ob-
served when lower doses are administered.
Conclusions
Our data showed that, with the methods employed,
MBPDT and PGPDT induced cell death to the three cer-
vical cancer cell lines analyzed, with predominant mor-
phological characteristics of necrosis and apoptosis,
respectively. However, none of the treatments activated
caspase-3.
We also observed that MBPDT, both as monotherapy
and as combined therapy with cisplatin, was able to in-
duce DNA double-strand breaks in the three cell lines
evaluated, while PGPDT did not. Despite its genotoxi-
city, MBPDT was not mutagenic since it inhibited the
proliferation capacity of surviving cells.
When combining PDT and cisplatin the advantages of
each individual treatment are enhanced. Low doses of
cisplatin administered prior to PGPDT optimized the
result, and MBPDT sensitized tumor cells for cisplatin
action. Taken together, those results elicit the potential
of such combined therapy in diminishing the toxicity of
antineoplastic drugs.
Ultimately, photodynamic therapy mediated by either
methylene blue or Photogem as monotherapy or in com-
bination with cisplatin has low mutagenic potential and
possibly high immunogenic potential, characteristics that
support its safe use in clinical practice for the treatment
of cervical cancer.
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